Literature DB >> 18304427

[Evaluation of the risk of clonorchiasis inducing primary hepatocellular carcinoma].

Sheng-Kui Tan1, Xiao-Qiang Qiu, Hong-Ping Yu, Xiao-Yun Zeng, Yin-Nong Zhao, Lang Hu.   

Abstract

OBJECTIVE: To explore the relationship between clonorchiasis and primary hepatocellular carcinoma (HCC) and analyze the synergistic actions of HBV infection, alcohol consumption and clonorchiasis on HCC development.
METHODS: This hospital-based case-control study was conducted among 444 HCC patients (cases) and 500 non tumor patients (controls) to compare the prevalence of clonorchiasis in the cases and the controls. The risk of clonorchiasis and the synergistic actions between HBV infection, alcohol consumption and clonorchiasis on HCC development were analyzed by crossover analysis and multiple logistic regression.
RESULTS: The prevalence of clonorchiasis in the cases (16.44%) was much higher than that of the controls (2.40%) (X2 = 56.58, P less than 0.01). In the case group, the OR value of those with clonorchiasis was 8.00 (95% CI: 4.34-14.92). The OR value was 4.82 (95% CI: 2.32-10.26) for the subjects whose clonorchiasis was diagnosed less than 10 years before their diagnosis of HCC, and was 17.54 (95% CI: 5.47-57.18) for those whose HCC was diagnosed more than 10 years ago. HBV infection, alcohol consumption and clonorchiasis showed an additive interaction in the development of HCC, with a relative excess risk of interaction of 110.43 and 18.23; attributable proportion of interaction of 0.80 and 0.63; synergy index of 5.18 and 2.84, respectively.
CONCLUSION: Clonorchiasis could be an important risk factor for HCC. When the course of clonorchiasis is prolonged, the risk of HCC could increase. HBV infection, alcohol consumption and clonorchiasis might have synergistic actions on the development of HCC.

Entities:  

Mesh:

Year:  2008        PMID: 18304427

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  6 in total

1.  Polymorphisms of alcohol dehydrogenase-2 and aldehyde dehydrogenase-2 and esophageal cancer risk in Southeast Chinese males.

Authors:  Jian-Hua Ding; Su-Ping Li; Hai-Xia Cao; Jian-Zhong Wu; Chang-Ming Gao; Ping Su; Yan-Ting Liu; Jian-Nong Zhou; Jun Chang; Gen-Hong Yao
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 2.  Association between Liver Fluke Infection and Hepatobiliary Pathological Changes: A Systematic Review and Meta-Analysis.

Authors:  Jing Xia; Shi-chen Jiang; Hong-Juan Peng
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

3.  Clonorchis sinensis infection and co-infection with the hepatitis B virus are important factors associated with cholangiocarcinoma and hepatocellular carcinoma.

Authors:  Yunliang Shi; Zhihua Jiang; Yichao Yang; Peiqiu Zheng; Haiyan Wei; Yuan Lin; Guoli Lv; Qingli Yang
Journal:  Parasitol Res       Date:  2017-08-12       Impact factor: 2.289

4.  Clonorchis sinensis granulin: identification, immunolocalization, and function in promoting the metastasis of cholangiocarcinoma and hepatocellular carcinoma.

Authors:  Caiqin Wang; Huali Lei; Yanli Tian; Mei Shang; Yinjuan Wu; Ye Li; Lu Zhao; Mengchen Shi; Xin Tang; Tingjin Chen; Zhiyue Lv; Yan Huang; Xiaoping Tang; Xinbing Yu; Xuerong Li
Journal:  Parasit Vectors       Date:  2017-05-25       Impact factor: 3.876

5.  Clonorchis sinensis Granulin Promotes Malignant Transformation of Hepatocyte Through EGFR-Mediated RAS/MAPK/ERK and PI3K/Akt Signaling Pathways.

Authors:  Caiqin Wang; Qing He; Yingxuan Yin; Yinjuan Wu; Xuerong Li
Journal:  Front Cell Infect Microbiol       Date:  2021-11-10       Impact factor: 5.293

6.  Molecular characterization of severin from Clonorchis sinensis excretory/secretory products and its potential anti-apoptotic role in hepatocarcinoma PLC cells.

Authors:  Xueqing Chen; Shan Li; Lei He; Xiaoyun Wang; Pei Liang; Wenjun Chen; Meng Bian; Mengyu Ren; Jinsi Lin; Chi Liang; Jin Xu; Zhongdao Wu; Xuerong Li; Yan Huang; Xinbing Yu
Journal:  PLoS Negl Trop Dis       Date:  2013-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.